medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университет10.59598/ME-2305-6053-2026-118-1-33-43medecol-1309Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSХронические диффузные заболевания печени. Регистрация и учет больных, значимость регистровChronic diffuse liver diseases. Patient registration and accounting, the importance of registriesАннаоразоваЗ. И.AnnaorazovaZ. I.

Зарина Ихтияркызы Аннаоразова

161200, г. Туркестан, пр. Б. Саттарханова, 29

Zarina Ikhtiyarkyzy Annaorazova

161200,  Turkestan с., Sattarkhanov ave., 29 B

zarina.annaorazova@ayu.eduОшибаеваА. Е.OshibaevaA. E.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzНускабаеваГ. О.NuskabayevaG. O.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzИскандироваЭ. Д.IskandirovaE. D.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzСаховаБ. О.SakhovaB. O.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzРсалиеваЖ. И.RsalievaZh. M.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzАязбаеваГ. Б.AyazbaevaG. B.

161200, г. Туркестан, пр. Б. Саттарханова, 29

161200,  Turkestan с., Sattarkhanov ave., 29 B

info@ayu.edu.kzКистаубаевМ. У.KistaubaevM. U.

г. Шымкент, ул. Жандосова, 52

160000, Shymkent с., Zhandosov str., 52

shgmb17@mail.ruМеждународный казахско-турецкий университет им. Ходжи Ахмета ЯсавиКазахстанKhoja Ahmet Yasawi International Kazakh-Turkish UniversityKazakhstanШымкентская городская многопрофильная больница №2КазахстанShymkent Multidisciplinary Hospital №2Kazakhstan202605072026013343Copyright © Аннаоразова З.И., Ошибаева А.Е., Нускабаева Г.О., Искандирова Э.Д., Сахова Б.О., Рсалиева Ж.И., Аязбаева Г.Б., Кистаубаев М.У., 20262026Аннаоразова З.И., Ошибаева А.Е., Нускабаева Г.О., Искандирова Э.Д., Сахова Б.О., Рсалиева Ж.И., Аязбаева Г.Б., Кистаубаев М.У.Annaorazova Z.I., Oshibaeva A.E., Nuskabayeva G.O., Iskandirova E.D., Sakhova B.O., Rsalieva Z.M., Ayazbaeva G.B., Kistaubaev M.U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/1309Цель

Цель. Изучить роль медицинских регистров в мониторинге, диагностике и лечении пациентов с хроническими заболеваниями печени, а также оценить международный опыт в этой области.

Материалы и методы

Материалы и методы. Был проведен обзор отечественных и зарубежных источников, включая клинические рекомендации (AASLD, EASL, KASL), эпидемиологические исследования и данные о работе крупных регистров (TARGET-LD, Global Liver Registry, DELIVER, MAFLD Registry, PBC Registry). Поиск литературы проводился за период с 2018 по 2025 год в международных научных базах данных: PUBMED/MEDLINE, Cochrane Library, ScienceDirect, а также в электронных библиотеках Wiley, Springer, Elsevier, Karger и на официальных сайтах профильных организаций (EASL, AASLD, KASL, ВОЗ).

Результаты и обсуждение

Результаты и обсуждение. Регистры обеспечивают централизованный сбор данных о пациентах с ХДЗП, способствуя стандартизации диагностики, оценке эффективности лечения, стратификации риска и формированию доказательной базы для принятия клинических решений. Международный опыт показывает большую важность таких систем для разработки национальных стратегий здравоохранения. Однако отсутствие единых стандартов и недостаточное финансирование особенно остро ощущается в странах с ограниченными ресурсами, что приводит к фрагментации данных и невозможности проведения аналогичных исследований.

Выводы

Выводы. Создание национальных регистров пациентов с ХБП в Казахстане и других странах СНГ позволит значительно улучшить качество медицинской помощи, обеспечить профессиональный подход и повысить эффективность диагностики и лечения на всех этапах.

Introduction

Introduction. Chronic diffuse liver diseases (CDLD), including non-alcoholic and metabolically associated fatty liver disease (MAFLD), remain the leading cause of liver failure, cirrhosis, and hepatocellular carcinoma. The increasing incidence of these diseases requires not only effective clinical approaches but also systematic patient monitoring.

Aim

Aim. To study the role of medical registries in monitoring, diagnosing, and treating patients with chronic diffuse liver diseases, and to evaluate international experience in this area.

Materials and methods

Materials and methods. A review of domestic and international sources was conducted, including clinical guidelines (AASLD, EASL, KASL), epidemiological studies, and descriptions of the functioning of large registries (TARGET-LD, Global Liver Registry, DELIVER, MAFLD Registry, PBC Registry). A literature search was conducted for the period from 2018 to 2025 in international scientific databases: PubMed/MEDLINE, Cochrane Library, ScienceDirect, as well as in the Wiley, Springer, Elsevier, and Karger online libraries and on the official websites of relevant organizations (EASL, AASLD, KASL, WHO).

Results and discussion

Results and discussion. Registers provide centralized data collection on patients with chronic kidney disease, facilitate standardized diagnostics, assess treatment effectiveness, stratify risks, and generate an evidence base for clinical decisions. International experience demonstrates the significant importance of such systems for developing national healthcare strategies. However, the lack of uniform standards and funding are particularly acute in resource-limited countries, leading to data fragmentation and the impossibility of conducting comparable studies.

Conclusion

Conclusion. The creation of national registries of patients with chronic diffuse liver disease in Kazakhstan and other CIS countries will significantly improve the quality of medical care, ensure a multidisciplinary approach, and increase the effectiveness of diagnosis and treatment at all stages.

хронические диффузные заболевания печенихронический гепатитметаболически ассоциированная жировая болезнь печенициррозрегистры заболеваний печениchronic diffuse liver diseasechronic hepatitisMAFLDcirrhosisliver disease registriesThis research was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant No. BR24992814)ReferencesSharma A., Nagalli S. Chronic Liver Disease https://www.ncbi.nlm.nih.gov/books/NBK554597/Sharma A., Nagalli S. Chronic Liver Disease https://www.ncbi.nlm.nih.gov/books/NBK554597/Gan C., Yuan Y., Shen H. Liver diseases: epidemiology, causes, trends and predictions. Sig. Transduct. Target Ther. 2025; 10: 33. https://doi.org/10.1038/s41392-024-02072-zGan C., Yuan Y., Shen H. Liver diseases: epide-miology, causes, trends and predictions. Sig. Transduct. Target Ther. 2025; 10: 33. https://doi.org/10.1038/s41392-024-02072-zCusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., Kashyap S., Mechanick J.I., Mouzaki M., Nadolsky K., Rinella M.E., Vos M.B., Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 2022; 28 (5): 528-562. https://doi.org/10.1016/j.eprac.2022.03.010Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., Kashyap S., Mechanick J.I., Mouzaki M., Nadolsky K., Rinella M.E., Vos M.B., Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 2022; 28 (5): 528-562. https://doi.org/10.1016/j.eprac.2022.03.010Kang S.H., Lee H.W., Yoo J.J., Cho Y., Kim S.U., Lee T.H. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2021; 27 (3): 363-401. https://doi.org/10.3350/cmh.2021.0178Kang S.H., Lee H.W., Yoo J.J., Cho Y., Kim S.U., Lee T.H. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2021; 27 (3): 363-401. https://doi.org/10.3350/cmh.2021.0178European Association for the Study of the Liver. EASL Clinical Practice Guidelines on noninvasive tests for evaluation of liver disease severity and prognosis – 2021 update. J. Hepatol. 2021; 75 (3): 659-689. https://doi.org/10.1016/j.jhep.2021.05.025European Association for the Study of the Liver. EASL Clinical Practice Guidelines on noninvasive tests for evaluation of liver disease severity and prognosis – 2021 update. J. Hepatol. 2021; 75 (3): 659-689. https://doi.org/10.1016/j.jhep.2021.05.025Ghelimici T., Lupasco I., Dumbrava V.-T., Berezovscaia E., Taran N., Golovatiuc L., Lupasco D., Harea G., Burda T. Assessment of the nutritional state of patients with chronic diffuse liver diseases. Public Health, Economy and Management in Medicine. 2023; 4 (97): 141-144. https://doi.org/10.52556/2587-3873.2023.4(97).24Ghelimici T., Lupasco I., Dumbrava V.-T., Berezovscaia E., Taran N., Golovatiuc L., Lupasco D., Harea G., Burda T. Assessment of the nutritional state of patients with chronic diffuse liver diseases. Public Health, Economy and Management in Medicine. 2023; 4 (97): 141-144. https://doi.org/10.52556/2587-3873.2023.4(97).24Ivancovsky Wajcman D., Byrne C.J., Dillon J.F., Brennan P.N., Villota-Rivas M., Younossi Z.M., Allen A.M., Crespo J., Gerber L.H., Lazarus J.V. A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024; 83 (5): 1303-1325. https://doi.org/10.1097/HEP.0000000000001058Ivancovsky Wajcman D., Byrne C.J., Dillon J.F., Brennan P.N., Villota-Rivas M., Younossi Z.M., Allen A.M., Crespo J., Gerber L.H., Lazarus J.V. A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024; 83 (5): 1303-1325. https://doi.org/10.1097/HEP.0000000000001058Barritt A.S., Yu F., Mospan A.R., Newsome P.N., Roden M., Morris H.L., Loomba R., Neuschwander-Tetri B.A. TARGET-NASH investigators. High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort. Am. J. Gastroenterol. 2024; 119 (8): 1624-1627. https://doi.org/10.14309/ajg.0000000000002796Barritt A.S., Yu F., Mospan A.R., Newsome P.N., Roden M., Morris H.L., Loomba R., Neuschwander-Tetri B.A. TARGET-NASH investigators. High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort. Am. J. Gastroenterol. 2024; 119 (8): 1624-1627. https://doi.org/10.14309/ajg.0000000000002796Hardy T., Wonders K., Younes R., Aithal G.P., Aller R., Allison M., Bedossa P., Betsou F., Boursier J., Brosnan M.J., Burt A., Cobbold J., Cortez-Pinto H., Day C.P., Dufour J.F., Ekstedt M., Francque S., Harrison S., Miele L., Nasr P., Papatheodoridis G., Petta S., Tiniakos D., Torstenson R., Valenti L., Holleboom A.G., Yki-Jarvinen H., Geier A., Romero-Gomez M., Ratziu V., Bugianesi E., Schattenberg J.M., Anstee Q.M. LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp. Clin. Trials. 2020; 98: 106175. https://doi.org/10.1016/j.cct.2020.106175Hardy T., Wonders K., Younes R., Aithal G.P., Aller R., Allison M., Bedossa P., Betsou F., Boursier J., Brosnan M.J., Burt A., Cobbold J., Cortez-Pinto H., Day C.P., Dufour J.F., Ekstedt M., Francque S., Harrison S., Miele L., Nasr P., Papatheodoridis G., Petta S., Tiniakos D., Torstenson R., Valenti L., Holleboom A.G., Yki-Jarvinen H., Geier A., Romero-Gomez M., Ratziu V., Bugianesi E., Schattenberg J.M., Anstee Q.M. LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp. Clin. Trials. 2020; 98: 106175. https://doi.org/10.1016/j.cct.2020.106175Moon A.M., Singal A.G., Tapper E.B. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18 (12): 2650-2666. https://doi.org/10.1016/j.cgh.2019.07.060Moon A.M., Singal A.G., Tapper E.B. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18 (12): 2650-2666. https://doi.org/10.1016/j.cgh.2019.07.060Alrubaiy L., Oztumer C.A. Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis. Cureus. 2022; 14 (5): e25247. https://doi.org/10.7759/cureus.25247Alrubaiy L., Oztumer C.A. Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis. Cureus. 2022; 14 (5): e25247. https://doi.org/10.7759/cureus.25247Kardashian A., Serper M., Terrault N., Nephew L.D. Health disparities in chronic liver disease. Hepatology. 2023; 77 (4): 1382-1403. https://doi.org/10.1002/hep.32743Kardashian A., Serper M., Terrault N., Nephew L.D. Health disparities in chronic liver disease. Hepatology. 2023; 77 (4): 1382-1403. https://doi.org/10.1002/hep.32743Khan R., Luo Y., Wu F. Machine learning based liver disease diagnosis: A systematic review. Neurocomputing. 2021; 468: 492-509. https://doi.org/10.1016/j.neucom.2021.08.138Khan R., Luo Y., Wu F. Machine learning based liver disease diagnosis: A systematic review. Neurocomputing. 2021; 468: 492-509. https://doi.org/10.1016/j.neucom.2021.08.138Ba-Ssalamah A., Bastati N., Wibmer A., Fragner R., Hodge J.C., Trauner M., Herold C.J., Bashir M.R., Van Beers B.E. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J. Magn. Reson. Imaging. 2017; 45 (3): 646-659. https://doi.org/10.1002/jmri.25518Ba-Ssalamah A., Bastati N., Wibmer A., Fragner R., Hodge J.C., Trauner M., Herold C.J., Bashir M.R., Van Beers B.E. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J. Magn. Reson. Imaging. 2017; 45 (3): 646-659. https://doi.org/10.1002/jmri.25518Taouli B., Alves F.C. Imaging biomarkers of diffuse liver disease: current status. Abdom. Radiol. (NY). 2020; 45 (11): 3381-3385. https://doi.org/10.1007/s00261-020-02619-yTaouli B., Alves F.C. Imaging biomarkers of diffuse liver disease: current status. Abdom. Radiol. (NY). 2020; 45 (11): 3381-3385. https://doi.org/10.1007/s00261-020-02619-yHagström H., Shang Y., Wester A., Widman L. Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). Scand. J. Gastroenterol. 2022; 57 (8): 978-983. https://doi.org/10.1080/00365521.2022.2051202Hagström H., Shang Y., Wester A., Widman L. Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). Scand. J. Gastroenterol. 2022; 57 (8): 978-983. https://doi.org/10.1080/00365521.2022.2051202Ghadimi M., Habibabadi R.R., Hazhirkarzar B., Shaghaghi M., Ameli S., Khoshpouri P., Ghasabeh M.A., Gurakar A., Pawlik T.M., Kamel I.R. Advances in Imaging of Diffuse Parenchymal Liver Disease. J. Clin. Gastroenterol. 2020; 54 (8): 682-695. https://doi.org/10.1097/MCG.0000000000001380Ghadimi M., Habibabadi R.R., Hazhirkarzar B., Shaghaghi M., Ameli S., Khoshpouri P., Ghasabeh M.A., Gurakar A., Pawlik T.M., Kamel I.R. Advances in Imaging of Diffuse Parenchymal Liver Disease. J. Clin. Gastroenterol. 2020; 54 (8): 682-695. https://doi.org/10.1097/MCG.0000000000001380Elbanna K.Y., Mansoori B., Mileto A., Rogalla P., S Guimarães L. Dual-energy CT in diffuse liver disease: is there a role? Abdom Radiol (NY). 2020; 45 (11): 3413-3424. https://doi.org/10.1007/s00261-020-02702-4Elbanna K.Y., Mansoori B., Mileto A., Rogalla P., S Guimarães L. Dual-energy CT in diffuse liver disease: is there a role? Abdom Radiol (NY). 2020; 45 (11): 3413-3424. https://doi.org/10.1007/ s00261-020-02702-4Bakulin I.G., Burlakova S.A., Skazyvaeva E.V., Skalinskaya M.I. Registry of patients with autoimmune liver diseases in St. Petersburg: clinical and epidemiological data. Bulletin of the North-West State Medical University named after I.I. Mechnikov. 2024; 16 (2): 61-72. https://doi.org/10.17816/mechnikov627505Bakulin I.G., Burlakova S.A., Skazyvaeva E.V., Skalinskaya M.I. Registry of patients with autoimmune liver diseases in St. Petersburg: clinical and epidemiological data. Bulletin of the North-West State Medical University named after I.I. Mechnikov. 2024; 16 (2): 61-72. https://doi.org/10.17816/mechnikov627505Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. https://doi.org/10.1016/j.jhep.2023.03.017Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. https://doi.org/10.1016/j.jhep.2023.03.017Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9 (6): 524-530.e1; quiz e60. https://doi.org/10.1016/j.cgh.2011.03.020Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9 (6): 524-530.e1; quiz e60. https://doi.org/10.1016/j.cgh.2011.03.020Kanwal F., Hernaez R., Liu Y., Taylor T.J., Rana A., Kramer J.R., Naik A.D., Smith D., Taddei T., Asch S.M. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Intern. Med. 2021; 181 (7): 949-959. https://doi.org/10.1001/jamainternmed.2021.2051Kanwal F., Hernaez R., Liu Y., Taylor T.J., Rana A., Kramer J.R., Naik A.D., Smith D., Taddei T., Asch S.M. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Intern. Med. 2021; 181 (7): 949-959. https://doi.org/10.1001/jamainternmed.2021.2051Samanta T., Park J.H., Kaipparettu B.A. Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer. Cancers (Basel). 2025; 17 (5): 844. https://doi.org/10.3390/cancers17050844Samanta T., Park J.H., Kaipparettu B.A. Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer. Cancers (Basel). 2025; 17 (5): 844. https://doi.org/10.3390/cancers17050844Valery P.C., Powell E., Moses N., Volk M.L., McPhail S.M., Clark P.J., Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open. 2015; 5 (4): e007451. https://doi.org/10.1136/bmjopen-2014-007451Valery P.C., Powell E., Moses N., Volk M.L., McPhail S.M., Clark P.J., Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open. 2015; 5 (4): e007451. https://doi.org/10.1136/bmjopen-2014-007451Hasjim B.J., Harris A., Balbale S.N., Obayemi J.E., Beestrum M., Polineni P., Paukner M., Mohammadi M., Dentici O.C., Kershaw K.N., Lewis-Thames M.W., Mehrotra S, Ladner D.P. Social Disadvantage and Disparities in Chronic Liver Disease: A Systematic Review. Am. J. Gastroenterol. 2024; 120 (7): 1548-1566. https://doi.org/10.14309/ajg.0000000000003171Hasjim B.J., Harris A., Balbale S.N., Obayemi J.E., Beestrum M., Polineni P., Paukner M., Mohammadi M., Dentici O.C., Kershaw K.N., Lewis-Thames M.W., Mehrotra S, Ladner D.P. Social Disadvantage and Disparities in Chronic Liver Disease: A Systematic Review. Am. J. Gastroenterol. 2024; 120 (7): 1548-1566. https://doi.org/10.14309/ajg.0000000000003171Naik A.D., Arney J., Clark J.A., Martin L.A., Walling A.M., Stevenson A., Smith D., Asch S.M., Kanwal F. Integrated Model for Patient-Centered Advanced Liver Disease Care. Clin. Gastroenterol. Hepatol. 2020; 18 (5): 1015-1024. https://doi.org/10.1016/j.cgh.2019.07.043Naik A.D., Arney J., Clark J.A., Martin L.A., Walling A.M., Stevenson A., Smith D., Asch S.M., Kanwal F. Integrated Model for Patient-Centered Advanced Liver Disease Care. Clin. Gastroenterol. Hepatol. 2020; 18 (5): 1015-1024. https://doi.org/10.1016/j.cgh.2019.07.043Ufere N.N., Lago-Hernandez C., Alejandro-Soto A., Walker T., Li L., Schoener K., Keegan E., Gonzalez C., Bethea E., Singh S., El-Jawahri A., Nephew L., Jones P., Serper M. Health care-related transportation insecurity is associated with adverse health outcomes among adults with chronic liver disease. Hepatol. Commun. 2024; 8 (1): e0358. https://doi.org/10.1097/HC9.0000000000000358Ufere N.N., Lago-Hernandez C., Alejandro-Soto A., Walker T., Li L., Schoener K., Keegan E., Gonzalez C., Bethea E., Singh S., El-Jawahri A., Nephew L., Jones P., Serper M. Health care-related transportation insecurity is associated with adverse health outcomes among adults with chronic liver disease. Hepatol. Commun. 2024; 8 (1): e0358. https://doi.org/10.1097/HC9.0000000000000358Capuano P., Hileman B., Tigano S., Magro B., Lo Re V., Liotta R., Sciveres M., Ranucci G., Provenzani A., Burgio G., Scardulla C., Arcadipane A., Martucci G. Telemedicine in Patients Affected by Chronic Liver Disease: A Scoping Review of Clinical Outcomes and the Devices Evaluated. J. Clin. Med. 2023; 12 (15): 5128. https://doi.org/10.3390/jcm12155128Capuano P., Hileman B., Tigano S., Magro B., Lo Re V., Liotta R., Sciveres M., Ranucci G., Provenzani A., Burgio G., Scardulla C., Arcadipane A., Martucci G. Telemedicine in Patients Affected by Chronic Liver Disease: A Scoping Review of Clinical Outcomes and the Devices Evaluated. J. Clin. Med. 2023; 12 (15): 5128. https://doi.org/10.3390/jcm12155128Verma M., Brahmania M., Fortune B.E., Asrani S.K., Fuchs M., Volk M.L. Patient-centered care: Key elements applicable to chronic liver disease. Hepatology. 2023; 78 (1): 307-318. https://doi.org/10.1002/hep.32618Verma M., Brahmania M., Fortune B.E., Asrani S.K., Fuchs M., Volk M.L. Patient-centered care: Key elements applicable to chronic liver disease. Hepatology. 2023; 78 (1): 307-318. https://doi.org/10.1002/hep.32618Mellinger J.L., Moser S., Welsh D.E., Yosef M.T., Van T., McCurdy H., Rakoski M.O., Moseley R.H., Glass L., Waljee A.K., Volk M.L., Sales A., Su G.L. Access to Subspecialty Care And Survival Among Patients With Liver Disease. Am. J. Gastroenterol. 2016; 111 (6): 838-44. https://doi.org/10.1038/ajg.2016.96Mellinger J.L., Moser S., Welsh D.E., Yosef M.T., Van T., McCurdy H., Rakoski M.O., Moseley R.H., Glass L., Waljee A.K., Volk M.L., Sales A., Su G.L. Access to Subspecialty Care And Survival Among Patients With Liver Disease. Am. J. Gastroenterol. 2016; 111 (6): 838-44. https://doi.org/10.1038/ajg.2016.96Fricker Z.P., Serper M. Current Knowledge, Barriers to Implementation, and Future Directions in Palliative Care for End-Stage Liver Disease. Liver Transpl. 2019; 25 (5): 787-796. https://doi.org/10.1002/lt.25434Fricker Z.P., Serper M. Current Knowledge, Barriers to Implementation, and Future Directions in Palliative Care for End-Stage Liver Disease. Liver Transpl. 2019; 25 (5): 787-796. https://doi.org/10.1002/lt.25434Muftah A.A., Banala C., Raasikh T., Jamali T., Bustamante G., Cholankeril G., Kanwal F., Flores A., Hernaez R. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023; 78 (1): 179-194. https://doi.org/10.1097/HEP.0000000000000265Muftah A.A., Banala C., Raasikh T., Jamali T., Bustamante G., Cholankeril G., Kanwal F., Flores A., Hernaez R. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023; 78 (1): 179-194. https://doi.org/10.1097/HEP.0000000000000265Wegermann K., Wilder J.M., Parish A., Niedzwiecki D., Gellad Z.F., Muir A.J., Patel Y.A. Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. Dig. Dis. Sci. 2022; 67 (1): 93-99. https://doi.org/10.1007/s10620-021-06842-5Wegermann K., Wilder J.M., Parish A., Niedzwiecki D., Gellad Z.F., Muir A.J., Patel Y.A. Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. Dig. Dis. Sci. 2022; 67 (1): 93-99. https://doi.org/10.1007/s10620-021-06842-5Rush B., Walley K.R., Celi L.A., Rajoriya N., Brahmania M. Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology. 2017; 66 (5): 1585-1591. https://doi.org/10.1002/hep.29297Rush B., Walley K.R., Celi L.A., Rajoriya N., Brahmania M. Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology. 2017; 66 (5): 1585-1591. https://doi.org/10.1002/hep.29297Psaraki A., Ntari L., Karakostas C., Korrou-Karava D., Roubelakis M.G. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology. 2022; 75 (6): 1590-1603. https://doi.org/10.1002/hep.32129Psaraki A., Ntari L., Karakostas C., Korrou-Karava D., Roubelakis M.G. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology. 2022; 75 (6): 1590-1603. https://doi.org/10.1002/hep.32129Ge J., Fontil V., Ackerman S., Pletcher M.J., Lai J.C. Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis. Hepatology. 2025; 81 (4): 1353-1364. https://doi.org/10.1097/HEP.0000000000000583Ge J., Fontil V., Ackerman S., Pletcher M.J., Lai J.C. Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis. Hepatology. 2025; 81 (4): 1353-1364. https://doi.org/10.1097/HEP.0000000000000583Su G.L., Glass L., Tapper E.B., Van T., Waljee A.K., Sales A.E. Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology. 2018; 68 (6): 2317-2324. https://doi.org/10.1002/hep.30074Su G.L., Glass L., Tapper E.B., Van T., Waljee A.K., Sales A.E. Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology. 2018; 68 (6): 2317-2324. https://doi.org/10.1002/hep.30074Moussa D., Flores J.E., Doyle J.S., Ryan M., Wallace J., Howell J. Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings. PLoS One. 2025; 20 (1): e0313216. https://doi.org/10.1371/journal.pone.0313216Moussa D., Flores J.E., Doyle J.S., Ryan M., Wallace J., Howell J. Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings. PLoS One. 2025; 20 (1): e0313216. https://doi.org/10.1371/journal.pone.0313216Aby E.S., Kaplan A. Addressing Social Determinants of Health to Achieve Equity in Liver Transplantation: Moving From Identification to Implementation. Transplantation. 2025; 109 (6): e266-e267. https://doi.org/10.1097/TP.0000000000005352Aby E.S., Kaplan A. Addressing Social Determinants of Health to Achieve Equity in Liver Transplantation: Moving From Identification to Implementation. Transplantation 2025 109 (6): e266-e267. https://doi.org/10.1097/TP.0000000000005352Yilma M., Dalal N., Wadhwani S.I., Hirose R., Mehta N. Geographic disparities in access to liver transplantation. Liver Transpl. 2023; 29 (9): 987-997. https://doi.org/10.1097/LVT.0000000000000182Yilma M., Dalal N., Wadhwani S.I., Hirose R., Mehta N. Geographic disparities in access to liver transplantation. Liver Transpl. 2023; 29 (9): 987-997. https://doi.org/10.1097/LVT.0000000000000182Schomerus G., Leonhard A., Manthey J., Morris J., Neufeld M., Kilian C., Speerforck S., Winkler P., Corrigan P.W. The stigma of alcohol-related liver disease and its impact on healthcare. J. Hepatol. 2022; 77 (2): 516-524. https://doi.org/10.1016/j.jhep.2022.04.026Schomerus G., Leonhard A., Manthey J., Morris J., Neufeld M., Kilian C., Speerforck S., Winkler P., Corrigan P.W. The stigma of alcohol-related liver disease and its impact on healthcare. J. Hepatol. 2022; 77 (2): 516-524. https://doi.org/10.1016/j.jhep.2022.04.026Sakowitz S., Bakhtiyar S.S., Mallick S., Kaldas F., Benharash P. Association of Community Socioeconomic Distress With Waitlist and Survival Outcomes in Liver Transplantation. Transplantation. 2025; 109 (6): 976-984. https://doi.org/10.1097/TP.0000000000005328Sakowitz S., Bakhtiyar S.S., Mallick S., Kaldas F., Benharash P. Association of Community Socioeconomic Distress With Waitlist and Survival Outcomes in Liver Transplantation. Transplantation. 2025; 109 (6): 976-984. https://doi.org/10.1097/TP.0000000000005328Kimbell B., Boyd K., Kendall M., Iredale J., Murray S.A. Managing uncertainty in advanced liver disease: a qualitative, multiperspective, serial interview study. BMJ Open. 2015; 5 (11): e009241. https://doi.org/10.1136/bmjopen-2015-009241Kimbell B., Boyd K., Kendall M., Iredale J., Murray S.A. Managing uncertainty in advanced liver disease: a qualitative, multiperspective, serial interview study. BMJ Open. 2015; 5 (11): e009241. https://doi.org/10.1136/bmjopen-2015-009241Hyde A.M., Watt M., Carbonneau M., Eboreime E.A., Abraldes J.G., Tandon P. Understanding Preferences Toward Virtual Care: A Pre-COVID Mixed Methods Study Exploring the Perspectives of Patients with Chronic Liver Disease. Telemed J. E. Health. 2022; 28 (3): 407-414. https://doi.org/10.1089/tmj.2021.0099Hyde A.M., Watt M., Carbonneau M., Eboreime E.A., Abraldes J.G., Tandon P. Understanding Preferences Toward Virtual Care: A Pre-COVID Mixed Methods Study Exploring the Perspectives of Patients with Chronic Liver Disease. Telemed J. E. Health. 2022; 28 (3): 407-414. https://doi.org/10.1089/tmj.2021.0099

The authors declare that there are no conflicts of interest present.